Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 2011. ,
Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?, Am Heart J, vol.151, pp.257-64, 2006. ,
User's guide to the medical literature: a manual for evidence-based clinical practice, pp.571-83, 2008. ,
The influence of study characteristics on reporting of subgroup analyses in randomized controlled trials: systematic review, BMJ, vol.342, p.1569, 2011. ,
Credibility of claims of subgroup effects in randomised controlled trials: systematic review, BMJ, vol.344, 2012. ,
Representation of the elderly, women, and minorities in heart failure clinical trials, Arch Intern Med, vol.162, issue.15, pp.1682-1690, 2002. ,
Confounding by indication in clinical research, JAMA, vol.316, issue.17, pp.1818-1827, 2016. ,
A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research, J Clin Epidemiol, vol.66, issue.8, pp.818-843, 2013. ,
Statistical problems in the reporting of clinical trials. A survey of three medical journals, N Engl J Med, vol.317, pp.426-458, 1987. ,
, The BMJ: leading general medical journal, The JAMA Network | Home of JAMA and the Specialty Journals of the American Medical Association
, The New England Journal of Medicine: Research & Review Articles
, PLOS Medicine: A Peer-Reviewed Open-Access Journal
Subgroup analysis and other (mis)uses of baseline data in clinical trials, Lancet, vol.355, pp.1064-1073, 2000. ,
Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation, Lancet, vol.365, issue.9454, pp.176-86, 2005. ,
Statistics in medicine reporting of subgroup analyses in clinical trials, N Engl J Med, vol.357, pp.2189-94, 2007. ,
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, J Clin Epidemiol, vol.62, issue.10, pp.1-34, 2009. ,
Dealing with heterogeneity of treatment effects: is the literature up to the challenge?, Trials, vol.10, p.43, 2009. ,
Estimation and reporting of heterogeneity of treatment effects. Developing an observational CER protocol: a user's guide, Chapter 3 ,
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials, JAMA, vol.266, pp.93-101, 1991. ,
A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas. 2011 Blackwell publishing ltd, Int J Clin Pract, vol.65, issue.8, pp.831-878, 2011. ,
Three simple rules to ensure reasonably credible subgroup analyses, BMJ, vol.351, p.5651, 2015. ,
Better reporting of randomized controlled trials: the CONSORT statement, BMJ, vol.313, issue.7057, pp.570-571, 1996. ,
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, PLoS Med, vol.4, issue.10, 2007. ,
Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses, Pharmacoepidemiol Drug Saf, vol.21, issue.7, pp.697-709, 2011. ,
Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry, Am J Psychiatry, vol.162, pp.1957-60, 2005. ,
, Abridged index medicus (aim or "core clinical") journal titles, 2015.
Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes, JAMA, vol.303, pp.2058-64, 2010. ,
Concepts of interaction, Am J Epidemiol, vol.112, pp.467-70, 1980. ,
Comparative effectiveness research: challenges for medical journals, Am J Manag Care, vol.16, issue.5, pp.131-134, 2010. ,
Subgroup analyses in randomized trials: risks of subgroupspecific analyses; power and sample size for the interaction test, J Clin Epidemiol, vol.57, pp.229-265, 2004. ,
For objective causal inference, design trumps analysis, Ann Appl Stat, vol.2, issue.3, pp.808-848, 2008. ,
The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses ,